Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2020

21.03.2019 | Original Research

Extended Gastrectomy for T4b Gastric Adenocarcinoma: Single-Surgeon Experience

verfasst von: Mushegh А. Sahakyan, Artak Gabrielyan, Hmayak Petrosyan, Shushan Yesayan, Sevak S. Shahbazyan, Arthur M. Sahakyan

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study reports single-surgeon experience with extended gastrectomy including en-bloc resection of adjacent organs/structures for T4b stage gastric adenocarcinoma. Time-related changes in patient selection criteria and outcomes were also analyzed.

Methods

All consecutive gastrectomies for adenocarcinoma performed between May 2004 and December 2017 were extracted from prospectively collected database to study surgical and oncologic results. Time-related changes in outcomes were examined according to three time periods.

Results

Five hundred eighty-seven gastrectomies were performed throughout the study period including 87 (14.8%) extended resections. The latter most often included pancreatosplenectomy, colon, and liver resections (21, 16, and 11 patients, respectively) resulting in similar postoperative outcomes and survival. Extended gastrectomy was associated with larger tumor size (8.4 vs 5.6 cm), performing total gastrectomy (55.2 vs 35.2%, p < 0.01) and increased blood loss (375 vs 150 ml, p < 0.01) compared with standard gastrectomy. Larger experience in extended gastrectomy allowed for expanding patient selection criteria, considering complex resections and extensive lymphadenectomy. Median and 3-year survival following extended gastrectomy for T4b adenocarcinoma were 14 months and 18%, respectively, which was comparable to standard gastrectomy for T4a adenocarcinoma (p = 0.48). Obesity, nodal stage and type of gastrectomy were associated with survival in T4b adenocarcinoma in the univariable analysis. Obesity and N3a and N3b stages were independent predictors in the multivariable model.

Conclusions

Extended gastrectomy for T4b gastric adenocarcinoma provides satisfactory surgical outcomes even with expanded patient selection criteria and regardless of the organ involved. Given its poor prognosis, neoadjuvant therapy should be considered to improve the long-term oncologic results.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRef
2.
Zurück zum Zitat Hamashima C, Ogoshi K, Narisawa R, Kishi T, Kato T, Fujita K, et al. Impact of endoscopic screening on mortality reduction from gastric cancer. World J Gastroenterol. 2015;21(8):2460–6.CrossRef Hamashima C, Ogoshi K, Narisawa R, Kishi T, Kato T, Fujita K, et al. Impact of endoscopic screening on mortality reduction from gastric cancer. World J Gastroenterol. 2015;21(8):2460–6.CrossRef
3.
Zurück zum Zitat Kim H, Hwang Y, Sung H, Jang J, Ahn C, Kim SG, et al. Effectiveness of gastric cancer screening on gastric cancer incidence and mortality in a community-based prospective cohort. Cancer Res Treat. 2018;50(2):582–9.CrossRef Kim H, Hwang Y, Sung H, Jang J, Ahn C, Kim SG, et al. Effectiveness of gastric cancer screening on gastric cancer incidence and mortality in a community-based prospective cohort. Cancer Res Treat. 2018;50(2):582–9.CrossRef
4.
Zurück zum Zitat Mita K, Ito H, Katsube T, Tsuboi A, Yamazaki N, Asakawa H, et al. Prognostic factors affecting survival after multivisceral resection in patients with clinical T4b gastric cancer. J Gastrointest Surg. 2017;21(12):1993–9.CrossRef Mita K, Ito H, Katsube T, Tsuboi A, Yamazaki N, Asakawa H, et al. Prognostic factors affecting survival after multivisceral resection in patients with clinical T4b gastric cancer. J Gastrointest Surg. 2017;21(12):1993–9.CrossRef
5.
Zurück zum Zitat Pacelli F, Cusumano G, Rosa F, Marrelli D, Dicosmo M, Cipollari C, et al. Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. JAMA surg. 2013;148(4):353–60.CrossRef Pacelli F, Cusumano G, Rosa F, Marrelli D, Dicosmo M, Cipollari C, et al. Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. JAMA surg. 2013;148(4):353–60.CrossRef
6.
Zurück zum Zitat Brar SS, Seevaratnam R, Cardoso R, Yohanathan L, Law C, Helyer L, et al. Multivisceral resection for gastric cancer: a systematic review. Gastric Cancer: Official Journal of the International Gastric Cancer. 2012;15(Suppl 1):S100–7.CrossRef Brar SS, Seevaratnam R, Cardoso R, Yohanathan L, Law C, Helyer L, et al. Multivisceral resection for gastric cancer: a systematic review. Gastric Cancer: Official Journal of the International Gastric Cancer. 2012;15(Suppl 1):S100–7.CrossRef
7.
Zurück zum Zitat Tran TB, Worhunsky DJ, Norton JA, Squires MH 3rd, Jin LX, Spolverato G, et al. Multivisceral resection for gastric cancer: results from the US gastric cancer collaborative. Ann Surg Oncol. 2015;22(Suppl 3):S840–7.CrossRef Tran TB, Worhunsky DJ, Norton JA, Squires MH 3rd, Jin LX, Spolverato G, et al. Multivisceral resection for gastric cancer: results from the US gastric cancer collaborative. Ann Surg Oncol. 2015;22(Suppl 3):S840–7.CrossRef
8.
Zurück zum Zitat Cheng CT, Tsai CY, Hsu JT, Vinayak R, Liu KH, Yeh CN, et al. Aggressive surgical approach for patients with T4 gastric carcinoma: promise or myth? Ann Surg Oncol. 2011;18(6):1606–14.CrossRef Cheng CT, Tsai CY, Hsu JT, Vinayak R, Liu KH, Yeh CN, et al. Aggressive surgical approach for patients with T4 gastric carcinoma: promise or myth? Ann Surg Oncol. 2011;18(6):1606–14.CrossRef
9.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer Staging Manual, vol. XV. 7th ed. New York: Springer-Verlag; 2010. p. 648. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer Staging Manual, vol. XV. 7th ed. New York: Springer-Verlag; 2010. p. 648.
10.
Zurück zum Zitat Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240(2):205–13.CrossRef Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240(2):205–13.CrossRef
11.
Zurück zum Zitat Min JS, Jin SH, Park S, Kim SB, Bang HY, Lee JI. Prognosis of curatively resected pT4b gastric cancer with respect to invaded organ type. Ann Surg Oncol. 2012;19(2):494–501.CrossRef Min JS, Jin SH, Park S, Kim SB, Bang HY, Lee JI. Prognosis of curatively resected pT4b gastric cancer with respect to invaded organ type. Ann Surg Oncol. 2012;19(2):494–501.CrossRef
12.
Zurück zum Zitat Zu G, Zhang T, Li W, Sun Y, Zhang X. Impact of clinicopathological parameters on survival after multiorgan resection among patients with T4 gastric carcinoma: a systematic review and meta-analysis. Clin Transl Oncol. 2017;19(6):750–60.CrossRef Zu G, Zhang T, Li W, Sun Y, Zhang X. Impact of clinicopathological parameters on survival after multiorgan resection among patients with T4 gastric carcinoma: a systematic review and meta-analysis. Clin Transl Oncol. 2017;19(6):750–60.CrossRef
13.
Zurück zum Zitat Ozer I, Bostanci EB, Orug T, Ozogul YB, Ulas M, Ercan M, et al. Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer. Am J Surg. 2009;198(1):25–30.CrossRef Ozer I, Bostanci EB, Orug T, Ozogul YB, Ulas M, Ercan M, et al. Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer. Am J Surg. 2009;198(1):25–30.CrossRef
14.
Zurück zum Zitat Li MZ, Deng L, Wang JJ, Xiao LB, Wu WH, Yang SB, et al. Surgical outcomes and prognostic factors of T4 gastric cancer patients without distant metastasis. PLoS One. 2014;9(9):e107061.CrossRef Li MZ, Deng L, Wang JJ, Xiao LB, Wu WH, Yang SB, et al. Surgical outcomes and prognostic factors of T4 gastric cancer patients without distant metastasis. PLoS One. 2014;9(9):e107061.CrossRef
15.
Zurück zum Zitat Kim JH, Jang YJ, Park SS, Park SH, Kim SJ, Mok YJ, et al. Surgical outcomes and prognostic factors for T4 gastric cancers. Asian J Surg. 2009;32(4):198–204.CrossRef Kim JH, Jang YJ, Park SS, Park SH, Kim SJ, Mok YJ, et al. Surgical outcomes and prognostic factors for T4 gastric cancers. Asian J Surg. 2009;32(4):198–204.CrossRef
16.
Zurück zum Zitat Wang HH, Li K, Xu H, Sun Z, Wang ZN, Xu HM. Improvement of T stage precision by integration of surgical and pathological staging in radically resected stage pT3-pT4b gastric cancer. Oncotarget. 2017;8(28):46506–13.PubMedPubMedCentral Wang HH, Li K, Xu H, Sun Z, Wang ZN, Xu HM. Improvement of T stage precision by integration of surgical and pathological staging in radically resected stage pT3-pT4b gastric cancer. Oncotarget. 2017;8(28):46506–13.PubMedPubMedCentral
17.
Zurück zum Zitat Lai KK, Fang WL, Wu CW, Huang KH, Chen JH, Lo SS, et al. Surgical impact on gastric cancer with locoregional invasion. World J Surg. 2011;35(11):2479–84.CrossRef Lai KK, Fang WL, Wu CW, Huang KH, Chen JH, Lo SS, et al. Surgical impact on gastric cancer with locoregional invasion. World J Surg. 2011;35(11):2479–84.CrossRef
18.
Zurück zum Zitat Luo H, Wu L, Huang M, Jin Q, Qin Y, Chen J. Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(43):e12932.CrossRef Luo H, Wu L, Huang M, Jin Q, Qin Y, Chen J. Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(43):e12932.CrossRef
19.
Zurück zum Zitat Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY, Keum KC, et al. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. World J Gastroenterol. 2015;21(9):2711–8.CrossRef Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY, Keum KC, et al. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. World J Gastroenterol. 2015;21(9):2711–8.CrossRef
20.
Zurück zum Zitat Kobayashi A, Nakagohri T, Konishi M, Inoue K, Takahashi S, Itou M, et al. Aggressive surgical treatment for T4 gastric cancer. J Gastrointest Surg. 2004;8(4):464–70.CrossRef Kobayashi A, Nakagohri T, Konishi M, Inoue K, Takahashi S, Itou M, et al. Aggressive surgical treatment for T4 gastric cancer. J Gastrointest Surg. 2004;8(4):464–70.CrossRef
21.
Zurück zum Zitat Dhar DK, Kubota H, Tachibana M, Kinugasa S, Masunaga R, Shibakita M, et al. Prognosis of T4 gastric carcinoma patients: an appraisal of aggressive surgical treatment. J Surg Oncol. 2001;76(4):278–82.CrossRef Dhar DK, Kubota H, Tachibana M, Kinugasa S, Masunaga R, Shibakita M, et al. Prognosis of T4 gastric carcinoma patients: an appraisal of aggressive surgical treatment. J Surg Oncol. 2001;76(4):278–82.CrossRef
22.
Zurück zum Zitat Onate-Ocana LF, Becker M, Carrillo JF, Aiello-Crocifoglio V, Gallardo-Rincon D, Brom-Valladares R, et al. Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. J Surg Oncol. 2008;98(5):336–42.CrossRef Onate-Ocana LF, Becker M, Carrillo JF, Aiello-Crocifoglio V, Gallardo-Rincon D, Brom-Valladares R, et al. Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. J Surg Oncol. 2008;98(5):336–42.CrossRef
Metadaten
Titel
Extended Gastrectomy for T4b Gastric Adenocarcinoma: Single-Surgeon Experience
verfasst von
Mushegh А. Sahakyan
Artak Gabrielyan
Hmayak Petrosyan
Shushan Yesayan
Sevak S. Shahbazyan
Arthur M. Sahakyan
Publikationsdatum
21.03.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00222-z

Weitere Artikel der Ausgabe 1/2020

Journal of Gastrointestinal Cancer 1/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.